Research Reports Initiation on Healthcare Stocks -- Valeant Pharma, Akorn, Universal Health Services, and LifePoint Health

NEW YORK, December 5, 2016 /PRNewswire/ --

In today's pre-market research, Stock-Callers.com directs investors' attention to the following Healthcare stocks: Valeant Pharmaceuticals International Inc. (NYSE: VRX), Akorn Inc. (NASDAQ: AKRX), Universal Health Services Inc. (NYSE: UHS), and LifePoint Health Inc. (NASDAQ: LPNT). On November 10th, 2016, research firm Charles Schwab gave the sector a "Market Perform" rating due to solid balance sheets, good dividend yields, an improved overall cost structure, and an increased demand for health care products and services. Additionally, valuations have appeared fair to slightly high throughout most of the sector. Learn more about these stocks by downloading their free report at:

http://stock-callers.com/registration

Valeant Pharma  

Last Friday, shares in Laval, Canada headquartered Valeant Pharmaceuticals International Inc. ended the session 0.91% higher at $15.45 with a total trading volume of 8.58 million shares. The stock is trading 26.13% below its 50-day moving average. Shares of the Company, which develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide, have a Relative Strength Index (RSI) of 34.53.

On November 23rd, 2016, research firm Mizuho downgraded the Company's stock rating from 'Neutral' to 'Underperform'. The research firm also revised downwards its previous target price from $25 to $11.

On November 29th, 2016, Valeant Pharmaceuticals announced that it has initiated a significant sales force expansion to focus on potential primary care physician prescribers of Xifaxan for irritable bowel syndrome with diarrhea (IBS-D) and Relistor for opioid induced constipation. The free research report on VRX is available at:

http://stock-callers.com/registration/?symbol=VRX

Akorn  

Lake Forest, Illinois headquartered Akorn Inc.'s stock declined 0.55%, to close the day at $19.88. A total volume of 1.77 million shares was traded, which was above their three months average volume of 1.42 million shares. The Company's shares are trading 19.53% below their 50-day moving average. Additionally, shares of Akorn, which develops, manufactures, and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter consumer health products and animal health pharmaceuticals in the US and internationally, have an RSI of 32.34.

On November 28th, 2016, Akorn announced that on November 22nd, 2016, the Patent Trial and Appeal Board ruled in favor of Akorn in its inter partes review proceeding and found all the claims of the 6,114,319 patent (" '319 patent") related to the Durezol® formulation to be obvious. The '319 patent, directed to emulsions of difluprednate, is owned by Senju Pharmaceutical Co., Ltd. and Mitsubishi Chemical Corporation, and licensed to Alcon Laboratories, Inc.

On December 01st, 2016, research firm Goldman initiated a 'Sell' rating on the Company's stock. The complimentary report on AKRX can be downloaded at:

http://stock-callers.com/registration/?symbol=AKRX

Universal Health Services  

Shares in King of Prussia, Pennsylvania headquartered Universal Health Services Inc. recorded a trading volume of 933,297 shares at the close of the last trading session, which was above their three months average volume of 874,070 shares. The stock ended the day 0.45% higher at $124.65. The Company's shares have advanced 3.19% in the last one month, 3.36% in the previous three months, and 4.66% on an YTD basis. The stock is trading above its 50-day moving average by 2.11%. Furthermore, shares of Universal Health Services, which through its subsidiaries, owns and operates acute care hospitals, behavioral health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers, have an RSI of 56.60.

On November 09th, 2016, research firm Mizuho downgraded the Company's stock rating from 'Buy' to 'Neutral', issuing a target price of $133 per share.

On November 16th, 2016, Universal Health Services announced that its Board of Directors voted to pay a cash dividend of $0.10 per share on December 15th, 2016 to shareholders of record as of December 01st, 2016. Visit us today and download our complete research report on UHS for free at:

http://stock-callers.com/registration/?symbol=UHS

LifePoint Health  

Brentwood, Tennessee-based LifePoint Health Inc.'s shares finished Friday's session 0.91% lower at $54.30. A total volume of 555,044 shares was traded, which was higher than their three months average volume of 543,080 shares. The stock is trading below its 50-day moving average by 6.77%. Furthermore, shares of LifePoint Health, which through its subsidiaries, owns and operates community hospitals, regional health systems, physician practices, outpatient centers, and post-acute facilities in the US, have an RSI of 40.41.

On November 02nd, 2016, LHC Group, Inc. and LifePoint Health® announced plans to form a joint venture to strengthen home health and hospice services across the country. The organizations have signed a definitive agreement to share ownership and governance of a new joint venture that will operate LifePoint's home health agencies and hospices, as well as select LHC Group agencies located near LifePoint hospitals.

On November 11th, 2016, research firm Credit Suisse downgraded the Company's stock rating from 'Outperform' to 'Neutral'. Get free access to your technical report on LPNT at:

http://stock-callers.com/registration/?symbol=LPNT

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://stock-callers.com/legal-disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA